A Phase III, Randomized, open labelled, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician’s choice of adjuvant endocrine monotheraphy in patients with estrogen receptor-positive, HER-2 negative early breast cancer (GO42784 – lidERA Breast Cancer)
Phase III, Subtype: ER+ and HER2-, Line of treatment: adjuvant therapy
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Aziera 03-79492120 (Research Room)
Pantai Hospital Sungai Petani
PRINCIPAL INVESTIGATOR
Dr Shazril Imran Shaukat
CONTACT
General line : 04 4428 888 (Ext. 8987)
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
Dr Fong Chin Heng
fongchinheng@gmail.com
CONTACT
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Azura Rozila Ahmad
drazura@beaconhospital.com.my
03 – 7787 2830
CONTACT
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel)
clinicalresearch@beaconhospital.com.my (Email)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
Dr Winnie Ng Nyek Ping
drwinnie@nci.gov.my
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)